Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6993745 | 0.89 | MAPT (0.43) | MAPTCACNA1BAPBA1MEN1KMT2A | |
| SCHEMBL1076421 | 0.88 | MAPT (0.46) | MAPTCACNA1BAPBA1MEN1KMT2A | |
| SCHEMBL1023939 | 0.88 | MAPT (0.60) | MAPTCACNA1BAPBA1MEN1KMT2A | |
| SCHEMBL2357850 | 0.86 | MAPT (0.44) | MAPTCACNA1BAPBA1MEN1KMT2A | |
| SCHEMBL9425493 | 0.86 | MAPT (0.48) | MAPTCACNA1BAPBA1MEN1KMT2A | |
| SCHEMBL7312659 | 0.83 | MAPT (0.50) | MAPTCACNA1BAPBA1MEN1KMT2A | |
| SCHEMBL328943 | 0.82 | — | — | |
| SCHEMBL890269 | 0.82 | — | — | |
| SCHEMBL28702820 | 0.81 | MAPT (0.41) | MAPTCACNA1BAPBA1MEN1KMT2A | |
| SCHEMBL28705970 | 0.81 | MAPT (0.41) | MAPTCACNA1BAPBA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604200-B2 | Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-12-10 | — | — | US | claimed |
| US-8138334-B2 | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | claimed |
| JP-4746878-B2 | — | — | 2011-08-10 | — | — | JP | claimed |
| JP-4674086-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| JP-4660199-B2 | — | — | 2011-03-30 | — | — | JP | claimed |
| EP-1581518-B1 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | claimed |
| US-20100292228-A1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-18 | — | — | US | claimed |
| US-7795261-B2 | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | claimed |
| EP-1858896-B1 | DIAZA-SPIRO-[4.4]-NONANE DERIVATIVES AS NEUROKININ (NK1) ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-18 | — | — | EP | claimed |
| EP-1874783-B1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-26 | — | — | EP | claimed |
| US-20060040950-A1 | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | claimed |
| WO-2005097774-A1 | SUBSTITUTED 4-ALKYL- AND 4-ALKANOYL-PIPERIDINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-20 | — | — | WO | claimed |
| EP-1581517-A1 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-AZETIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-05 | — | — | EP | claimed |
| EP-1581518-A2 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-05 | — | — | EP | claimed |
| EP-1551804-A1 | SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2005-07-13 | — | — | EP | claimed |
| WO-2004056800-A1 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-AZETIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056799-A2 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | claimed |
| WO-2004033428-A1 | SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-04-22 | — | — | WO | claimed |
| US-3991040-A | Aromatic imidodicarboxylic acid diallyl esters, prepolymers thereof, cured resins thereof, and processes for producing these | TEIJIN LIMITED (JA) | 1976-11-09 | — | — | US | claimed |
| US-3931224-A | Aromatic imidodicarboxylic acid diallyl esters, prepolymers thereof, cured resins thereof, and processes for producing these | TEIJIN LIMITED (JA) | 1976-01-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292228-A1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | NPSR1, OPRK1, PROKR2 | MAPT 3836/4885CACNA1B 1524/4885APBA1 3298/4885 |
| US-20060040950-A1 | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | NPSR1, TACR1, VIP | MAPT 3368/4885CACNA1B 1712/4885APBA1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.